JP2024525145A5 - - Google Patents
Info
- Publication number
- JP2024525145A5 JP2024525145A5 JP2023576415A JP2023576415A JP2024525145A5 JP 2024525145 A5 JP2024525145 A5 JP 2024525145A5 JP 2023576415 A JP2023576415 A JP 2023576415A JP 2023576415 A JP2023576415 A JP 2023576415A JP 2024525145 A5 JP2024525145 A5 JP 2024525145A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- pharmaceutical composition
- composition according
- compound
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/100466 | 2021-06-17 | ||
| CN2021100466 | 2021-06-17 | ||
| CNPCT/CN2022/091677 | 2022-05-09 | ||
| CN2022091677 | 2022-05-09 | ||
| PCT/CN2022/099089 WO2022262796A1 (en) | 2021-06-17 | 2022-06-16 | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525145A JP2024525145A (ja) | 2024-07-10 |
| JP2024525145A5 true JP2024525145A5 (https=) | 2025-06-03 |
Family
ID=82196389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576415A Pending JP2024525145A (ja) | 2021-06-17 | 2022-06-16 | がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4355747A1 (https=) |
| JP (1) | JP2024525145A (https=) |
| KR (1) | KR20240021808A (https=) |
| CN (2) | CN117597348A (https=) |
| AU (1) | AU2022292697A1 (https=) |
| CA (1) | CA3220099A1 (https=) |
| CL (1) | CL2023003731A1 (https=) |
| CO (1) | CO2023018577A2 (https=) |
| DO (1) | DOP2023000260A (https=) |
| IL (1) | IL309359A (https=) |
| MX (1) | MX2023014890A (https=) |
| PE (1) | PE20240923A1 (https=) |
| PH (1) | PH12023553300A1 (https=) |
| TW (1) | TW202315636A (https=) |
| UY (1) | UY39823A (https=) |
| WO (1) | WO2022262796A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| EP4698182A1 (en) | 2023-04-17 | 2026-02-25 | Janssen Pharmaceutica NV | Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder |
| WO2025082444A2 (en) | 2023-10-20 | 2025-04-24 | Janssen Pharmaceutica Nv | (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102984941B (zh) | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| TW202525813A (zh) * | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
-
2022
- 2022-06-16 WO PCT/CN2022/099089 patent/WO2022262796A1/en not_active Ceased
- 2022-06-16 PE PE2023003361A patent/PE20240923A1/es unknown
- 2022-06-16 PH PH1/2023/553300A patent/PH12023553300A1/en unknown
- 2022-06-16 CN CN202280043068.0A patent/CN117597348A/zh active Pending
- 2022-06-16 CA CA3220099A patent/CA3220099A1/en active Pending
- 2022-06-16 KR KR1020237043027A patent/KR20240021808A/ko active Pending
- 2022-06-16 CN CN202410890382.3A patent/CN118852178A/zh active Pending
- 2022-06-16 TW TW111122342A patent/TW202315636A/zh unknown
- 2022-06-16 EP EP22733288.9A patent/EP4355747A1/en active Pending
- 2022-06-16 AU AU2022292697A patent/AU2022292697A1/en active Pending
- 2022-06-16 JP JP2023576415A patent/JP2024525145A/ja active Pending
- 2022-06-16 IL IL309359A patent/IL309359A/en unknown
- 2022-06-16 MX MX2023014890A patent/MX2023014890A/es unknown
- 2022-06-17 UY UY0001039823A patent/UY39823A/es unknown
-
2023
- 2023-11-28 DO DO2023000260A patent/DOP2023000260A/es unknown
- 2023-12-13 CL CL2023003731A patent/CL2023003731A1/es unknown
- 2023-12-28 CO CONC2023/0018577A patent/CO2023018577A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525145A5 (https=) | ||
| US9199979B2 (en) | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | |
| RU2485122C2 (ru) | Соединения и композиции, ингибирующие parp, и способы их применения | |
| JP2015512942A5 (https=) | ||
| CA2850564A1 (en) | Compounds useful as inhibitors of atr kinase | |
| EP2868660B1 (en) | Antitumor effect potentiator comprising an imidazooxazine compound | |
| US20090093495A1 (en) | Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases | |
| US12084431B2 (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
| CN105592850B (zh) | Ack1/tnk2酪氨酸激酶的抑制剂 | |
| WO2017049462A1 (zh) | 一类新型的flt3激酶抑制剂及其用途 | |
| TWI453201B (zh) | 可作為Hsp90之抑制劑之異吲哚衍生物 | |
| JP2022523368A5 (https=) | ||
| CN112236426A (zh) | 制备2,4,5-三取代的1,2,4-三唑酮的方法 | |
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| CA2671336A1 (en) | Epothilone analogues modified at positions c12-c13 as anticancer drugs | |
| TW202245746A (zh) | Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途 | |
| CA3195465A1 (en) | Succinate and crystal form thereof as therapeutics | |
| CA2632149C (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| CN113382997A (zh) | 盐酸罗加替尼的一水合物及其固体状态 | |
| CN112442105B (zh) | 作为蛋白激酶抑制剂的嘧啶并[4,5-d]嘧啶-2-酮衍生物 | |
| WO2022083679A1 (en) | Prodrugs for sustained releasing therapeutic agents and uses thereof | |
| JP2022534429A5 (https=) | ||
| KR102759785B1 (ko) | CCL2 발현을 억제하는 1-aryloxymethyl-2,4,5-trifluorobenzene 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| EP2924045A1 (en) | New agents for the treatment of cancer | |
| WO2016197981A1 (zh) | 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用 |